See also this year's filing and all EDGAR filings for this company.
PDF Report 0001652130_2022_Intellia_Therapeutics_Inc.pdf
Logs
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2': 3, '100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 8}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001652130, Intellia Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 0 |
| 1 | LiabilitiesCurrent | 125,833,000 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 769,303,000 |
| 4 | AssetsNoncurrent | 474,635,000 |
| 5 | PropertyPlantAndEquipmentNet | 20,968,000 |
| 6 | Goodwill | 0 |
| 7 | remainder_Assets | 29,558,000 |
| 8 | GeneralAndAdministrativeExpense | 71,096,000 |
| 9 | ResearchAndDevelopmentExpense | 229,807,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 33,053,000 |
| 12 | remainder_NetIncome | 42,000 |
| 13 | remainder_ComprehensiveNetIncome | -2,633,000 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 125,833,000 |
| 1 | Assets | 1,294,464,000 |
| 2 | Expenses | 300,903,000 |
| 3 | Revenues | 33,053,000 |
| 4 | StockholdersEquity | 1,168,631,000 |
| 5 | NetIncome | -267,808,000 |
| 6 | ComprehensiveNetIncome | -269,124,500 |
| 7 | BaseVar | 878,464,000 |
| 8 | EconomicCapitalRatio | 1.02 |
Edgar->Model Mapping
Feature Distribution
Change over Time
